Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study-Reference-Cited by-同舟云学术

Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study

Published:2015-10-05 Issue:3 Volume:56 Page:330-339
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Ravenstijn Paulien¹,Remmerie Bart¹,Savitz Adam²,Samtani Mahesh N.³,Nuamah Isaac²,Chang Cheng-Tao³,De Meulder Marc¹,Hough David²,Gopal Srihari²

Affiliation:

1. Janssen Research & Development; a Division of Janssen Pharmaceutica NV; Beerse Belgium

2. Janssen Research & Development; Titusville NJ USA

3. Janssen Research & Development; Raritan NJ USA

Funder

Janssen Research & Development

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcph.597/fullpdf

Reference25 articles.

1. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia;Coppola;BMC Psychiatry,2012

2. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia;Gopal;J Psychopharmacol,2011

3. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies;Haddad;Patient Relat Outcome Meas,2014

4. Predictors of relapse in the year after hospital discharge among patients with schizophrenia;Schennach;Psychiatr Serv,2012

5. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia;Li;Prog Neuropsychopharmacol Biol Psychiatry,2011

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective;Molecular Pharmaceutics;2024-08-19

2. Model-Informed Clinical Development of 6-Monthly Injection of Paliperidone Palmitate in Patients with Schizophrenia: Dosing Strategies Guided by Population Pharmacokinetic Modeling and Simulation (Part II);European Journal of Drug Metabolism and Pharmacokinetics;2024-05-20

3. Evaluating the 6-month formulation of paliperidone palmitate: a twice-yearly injectable treatment for schizophrenia in adults;Expert Review of Neurotherapeutics;2024-03-06

4. Prodrugs as empowering tools in drug discovery and development: recent strategic applications of drug delivery solutions to mitigate challenges associated with lead compounds and drug candidates;Chemical Society Reviews;2024

5. Using in silico methods to determine optimal tapering regimens for decanoate-based long-acting injectable psychosis drugs;Therapeutic Advances in Psychopharmacology;2024-01